LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.99 USD -9.17% Market Closed
Market Cap: 26m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Operating Expenses
-$46.5m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Operating Expenses
-$269.7m
CAGR 3-Years
-6%
CAGR 5-Years
-25%
CAGR 10-Years
-34%
ProQR Therapeutics NV
NASDAQ:PRQR
Operating Expenses
-€48m
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Operating Expenses
-$196.8m
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
-15%
argenx SE
XBRU:ARGX
Operating Expenses
-$2.2B
CAGR 3-Years
-31%
CAGR 5-Years
-57%
CAGR 10-Years
-83%
Merus NV
NASDAQ:MRUS
Operating Expenses
-$266.9m
CAGR 3-Years
-26%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
26m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.18 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Operating Expenses?
Operating Expenses
-46.5m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Operating Expenses amounts to -46.5m USD.

What is LAVA Therapeutics NV's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-36%

Over the last year, the Operating Expenses growth was 14%. The average annual Operating Expenses growth rates for LAVA Therapeutics NV have been -36% over the past three years .

Back to Top